Ask AI
Bill117th CongressFiled Apr 28, 2021Health
S. 1425

Stop STALLING Act

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary reported to senate (Dec 8, 2021)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

What just happenedDec 8, 2021

Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.

Who’s behind it

Sen. Klobuchar, Amy [D-MN](D-MN)Sponsor
9 cosponsors5 D4 R
Read on Congress.gov
9cosponsors1committees6actions1related bills10subjects
  1. Dec 8, 2021Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 179.

  2. Dec 8, 2021Committee

    Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.

    Judiciary Committee
  3. Dec 8, 2021Committee14000

    Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.

    Judiciary Committee
  4. Jul 29, 2021Committee

    Committee on the Judiciary. Ordered to be reported without amendment favorably.

    Judiciary Committee
  5. Apr 28, 2021IntroReferral

    Read twice and referred to the Committee on the Judiciary.

    Judiciary Committee
  6. Apr 28, 2021IntroReferral10000

    Introduced in Senate

Reported to SenateDec 8, 202125

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Introduced in SenateApr 28, 2021

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Stop STALLING Act — Informed